Affordable Access

deepdyve-link
Publisher Website

E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells.

Authors
  • Aydemİr Çoban, Esra1
  • Tecİmel, Didem1, 2
  • KaŞikci, Ezgi1, 3
  • Bayrak, Ömer Faruk1, 2
  • Şahİn, Fikrettin1
  • 1 Department of Genetics and Bioengineering, Engineering Faculty, Yeditepe University, İstanbul Turkey. , (Turkey)
  • 2 Department of Medical Genetics, Faculty of Medicine, Yeditepe University, Yeditepe University Hospital, İstanbul Turkey. , (Turkey)
  • 3 Department of Microbiology & Immunology, Albert Einstein College of Medicine, New York, NY USA.
Type
Published Article
Journal
Turkish journal of biology = Turk biyoloji dergisi
Publication Date
Jan 01, 2020
Volume
44
Issue
5
Pages
230–237
Identifiers
DOI: 10.3906/biy-1912-60
PMID: 33110361
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Pancreatic ductal adenocarcinoma (PDAC) pathology is known for its uncontrollable progress due to highly invasive characteristics and refractory behavior against existing chemotherapies. The aberrant expression of CDH1 (expresses the protein E-cadherin) is associated with increased overall survival in various cancers, however, E-cadherin expression in PDAC progression has remained elusive. We investigated the impact of exogenously elevated E-cadherin levels on the tumorigenicity of transduced low grade and metastatic PDAC cell lines, Panc-1 and AsPC-1, respectively. Constitutive expression of E-cadherin promoted a more hybrid E/M state in AsPC-1 cells, while it was associated with the acquisition of a more epithelial-like state in Panc1 cells. Our study suggests that E-cadherin may play differential roles in determining the metastatic characteristics of primary and metastatic pancreatic cancer cells. Copyright © 2020 The Author(s).

Report this publication

Statistics

Seen <100 times